Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

作者：Zhenggang Ren, Jianming Xu, Yuxian Bai, Aibing Xu, Shundong Cang, Chengyou Du, Qiu Li, Yinying Lu, Yajin Chen, Yabing Guo, Zhendong Chen, Baorui Liu, Weidong Jia, Jian Wu, Junye Wang, Guoliang Shao, Bixiang Zhang, Yunfeng Shan, Zhiqiang Meng, Jianbing Wu, Shanzhi Gu, Wei Yang, Chao Liu, Xuetao Shi, Zhenyuan Gao, Tao Yin, Jiuwei Cui, Ming Huang, Bao-Cai Xing, Yilei Mao, Gao‐Jun Teng, Yanru Qin, Jinhai Wang, Feng Xia, Guowen Yin, Yong Yang, Mingxia Chen, Yan Wang, Hui Zhou, Jia Fan · 发表于：The Lancet Oncology · 年份：2021 · DOI：10.1016/s1470-2045(21)00252-7 · 被引用次数：1148 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Cancer Immunotherapy and Biomarkers、Colorectal Cancer Treatments and Studies